Comparing Pneumonia Risks of Budesonide with Fluticasone Among Patients with Asthma in Hong Kong: A Territory-Wide Retrospective Study.

INTRODUCTION

Interclass difference in pneumonia risks between budesonide (BUD) and fluticasone were not well studied in asthma.

METHODS

A territory-wide retrospective cohort study was conducted in Hong Kong among adult patients with Global Initiative for Asthma (GINA) step 3 to 5 asthma to examine pneumonia risks among those prescribed BUD or fluticacone (fluticasone furoate (FF) or fluticasone propionate (FP)).

RESULTS

There were 16,170 patients included with 7169 (44.3%), 7853 (48.6%), and 1148 (7.1%) of them prescribed BUD, FP, and FF, respectively. Using BUD as the reference group, the adjusted odds ratio (aOR), adjusted incidence rate ratio (aIRR), and adjusted hazard ratio (aHR) for all pneumonia events were 0.95 (0.85-1.06, p = 0.32), 1.05 (95% CI 0.99-1.12, p = 0.14), and 0.94 (95% CI 0.86-1.04, p = 0.23) for fluticasone (FF/FP), respectively. The aOR, aIRR, and aHR for hospitalized pneumonia were 0.95 (95% CI 0.84-1.07, p = 0.39), 1.15 (95% CI 0.63-2.08, p = 0.65), and 1.03 (95% CI 0.96-1.16, p = 0.39) for fluticasone (FF/FP). The aOR, aIRR, and aHR for pneumonia requiring ICU admissions were 1.08 (95% CI 0.58-2.00, p = 0.50), 1.15 (95% CI 0.63-2.08, p = 0.65), and 1.06 (95% CI 0.57-1.97 p = 0.85) for fluticasone (FF/FP), respectively. No significant difference in pneumonia risks for BUD and fluticasone (FF/FP) were observed.

CONCLUSION

There was no significant difference in pneumonia risks for BUD and fluticasone (FF/FP) among patients with moderate to severe asthma.